Practical Aspects of Chimeric Antigen Receptor T-cell Administration: From Commercial to Point-of-care Manufacturing

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 14

PMID 36238283

Authors

Nuria Martinez-Cibrian

Marta Espanol-Rego

Mariona Pascal

Julio Delgado

Valentin Ortiz-Maldonado

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions. In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel, ARI-0001 cells) has been extraordinarily approved under the Hospital Exemption clause for the treatment of patients older than 25 years of age with R/R acute lymphoblastic leukaemia. Var-cel has also been granted PRIority MEdicines designation by the European Medicines Agency for the same indication. In this review we reveal some practical aspects related to the preparation and administration of academic point-of-care CART-cell products, using var-cel as an example, and put them into the context of commercial products.

Citing Articles

Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer.

Luostarinen A, Vuorela A, Kerkela E, Patrikoski M, Kotovuori A, Koski J Sci Rep. 2025; 15(1):8093.

PMID: 40057567 PMC: 11890757. DOI: 10.1038/s41598-025-92736-9.

Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy.

Zhang S, Peng L, Chen Y, Xu Y, Moradi V Inflamm Regen. 2024; 44(1):45.

PMID: 39490997 PMC: 11533312. DOI: 10.1186/s41232-024-00358-x.

Advances in manufacturing chimeric antigen receptor immune cell therapies.

Ramamurthy A, Tommasi A, Saha K Semin Immunopathol. 2024; 46(5):12.

PMID: 39150566 DOI: 10.1007/s00281-024-01019-4.

Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma.

Medina-Olivares F, Gomez-De Leon A, Ghosh N Front Oncol. 2024; 14:1397613.

PMID: 39099684 PMC: 11294242. DOI: 10.3389/fonc.2024.1397613.

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.

Bui T, Mei H, Sang R, Ortega D, Deng W EBioMedicine. 2024; 106:105266.

PMID: 39094262 PMC: 11345408. DOI: 10.1016/j.ebiom.2024.105266.

References

Juan M, Delgado J, Calvo G, Trias E, Urbano-Ispizua A . Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001. Hum Gene Ther. 2021; 32(19-20):1004-1007. DOI: 10.1089/hum.2021.168. View

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

Panch S, Srivastava S, Elavia N, McManus A, Liu S, Jin P . Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. Mol Ther. 2019; 27(7):1275-1285. PMC: 6612799. DOI: 10.1016/j.ymthe.2019.05.015. View

Shah B, Ghobadi A, Oluwole O, Logan A, Boissel N, Cassaday R . KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502. PMC: 11613962. DOI: 10.1016/S0140-6736(21)01222-8. View

Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W . Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53. PMC: 5594743. DOI: 10.1056/NEJMoa1509277. View

Ortiz-Maldonado V, Rives S, Castella M, Alonso-Saladrigues A, Benitez-Ribas D, Caballero-Banos M . CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 Relapsed/Refractory Malignancies. Mol Ther. 2020; 29(2):636-644. PMC: 7854276. DOI: 10.1016/j.ymthe.2020.09.027. View

Adriaansen J, Stanton J, Schaut W, Bowden R . Compliance and cost control for cryopreservation of cellular starting materials: An industry perspective. Cytotherapy. 2022; 24(7):750-753. DOI: 10.1016/j.jcyt.2022.02.004. View

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

Ortiz-Maldonado V, Rives S, Espanol-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L . Factors associated with the clinical outcome of patients with relapsed/refractory CD19 acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. J Immunother Cancer. 2021; 9(12). PMC: 8671976. DOI: 10.1136/jitc-2021-003644. View

10.

Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B . KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020; 382(14):1331-1342. PMC: 7731441. DOI: 10.1056/NEJMoa1914347. View

11.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

12.

Jain T, Litzow M . No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv. 2018; 2(22):3393-3403. PMC: 6258912. DOI: 10.1182/bloodadvances.2018020198. View

13.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

14.

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

15.

Hay K, Gauthier J, Hirayama A, Voutsinas J, Wu Q, Li D . Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019; 133(15):1652-1663. PMC: 6460418. DOI: 10.1182/blood-2018-11-883710. View

16.

Castella M, Caballero-Banos M, Ortiz-Maldonado V, Gonzalez-Navarro E, Sune G, Antonana-Vidosola A . Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Front Immunol. 2020; 11:482. PMC: 7259426. DOI: 10.3389/fimmu.2020.00482. View

17.

Jacobson C, Chavez J, Sehgal A, William B, Munoz J, Salles G . Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2021; 23(1):91-103. DOI: 10.1016/S1470-2045(21)00591-X. View

18.

Roddie C, Dias J, OReilly M, Abbasian M, Cadinanos-Garai A, Vispute K . Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021; 39(30):3352-3363. PMC: 8791810. DOI: 10.1200/JCO.21.00917. View

19.

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

20.

Myers R, Taraseviciute A, Steinberg S, Lamble A, Sheppard J, Yates B . Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol. 2021; 40(9):932-944. PMC: 8937010. DOI: 10.1200/JCO.21.01405. View